olaratumab
Sign in to saveAlso known as Lartruvo, IMC-3G3, LY-3012207
Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
Research
131 papers- Olaratumab.2006
- Olaratumab: First Global Approval.Drugs · 2017
- Olaratumab.2012
- Olaratumab for the treatment of soft-tissue sarcoma.Future oncology (London, England) · 2017
- Olaratumab in the management of advanced soft tissue sarcoma.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2019
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Manufacturer
- Eli Lilly and Company
- Has use
- medication
Show 5 more facts
- medical condition treated
- soft-tissue sarcoma
- World Health Organisation international non-proprietary name
- olaratumab
- chemical formula
- C₆₅₅₄H₁₀₀₇₆N₁₇₃₆O₂₀₄₈S₄₀
- side effect
- neutropenia
- subject has role
- monoclonal antibody
Sources (3)
via Wikidata · CC0
~4 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- References
Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.
It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses").
Excerpted from Wikipedia’s “olaratumab” article, available under the CC BY-SA 4.0 licence.